China's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt

Clover Biopharmaceuticals

25/08/2026 23:24

Overview
China vaccine developer's H1 revenue dropped sharply after ending AdimFlu-S (QIS) sales in China
Company swung to net profit on one-off GAVI settlement gain
R&D expenses rose as company increased investment in respiratory vaccine candidates
Due to current liquidity position, expected future cash requirements and contractual obligations, the group has given careful consideration to its ability to continue as a going concern

Outlook
Clover will continue to prioritize resources for respiratory vaccine candidate development
Company says it will maintain focus on financial sustainability and operational efficiency

Result Drivers
ADIMFLU-S TERMINATION - Revenue fell sharply after company ended commercial activities of AdimFlu-S (QIS) in mainland China
GAVI SETTLEMENT - Net profit was mainly driven by a one-off accounting gain from GAVI settlement
RESPIRATORY VACCINE INVESTMENT - R&D expenses increased as company continued to invest in respiratory vaccine candidates

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 179,000
 
H1 Net Income Attributable
 
RMB 955 mln
 

Reuters Recommended Reads
Aug 25 - China's Innovent Biologics H1 revenue, profit rise on strong product sales
Aug 25 - Austar Lifesciences H1 profit drops on higher R&D spending
Aug 24 - Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-25/e9579f98-c062-469e-ad58-3fc74830bbf4.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)